-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $40

Benzinga·08/01/2025 14:11:05
Listen to the news
Cantor Fitzgerald analyst Steve Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $39 to $40.